Medical device manufacturers must maintain structured device information across regulatory databases such as FDA GUDID, EUDAMED, AusUDID, and swissdamed. As product portfolios and geographic reach grow, manually entering and maintaining this information can become difficult to scale.

The challenge is not simply volume. Each regulatory database has its own data requirements, business rules, submission methods, technical specifications, and processes for creating and updating device records.

For manufacturers with larger portfolios or frequent registration activity, machine-to-machine (M2M) integration can provide a more scalable approach.

That creates an important decision:

Should you build and maintain M2M regulatory connections internally, or buy a commercial UDI platform that already provides them?

The answer should consider more than initial cost. Implementation speed, regulatory coverage, internal expertise, ongoing maintenance and validation, scalability, and long-term ownership all matter.

First: Do You Actually Need M2M?

M2M is not automatically the right choice for every manufacturer.

Regulatory authorities may provide several submission methods depending on the market. EUDAMED, for example, supports direct user-interface entry, XML upload/download, and automated M2M data exchange.

The European Commission currently provides general volume-based guidance for choosing among these methods:

• Up to 100 devices: User interface may be appropriate
• 100–1,000 devices: XML upload/download may be appropriate
• More than 1,000 devices: M2M may be appropriate

These are guidelines rather than universal thresholds. Submission frequency, number of markets, internal resources, data complexity, and expected portfolio growth should also influence the decision.

Other regulatory databases provide different submission options. GUDID supports manual entry and HL7 SPL/XML submissions. AusUDID supports four methods: individual record entry through the online portal, bulk upload using Excel template, M2M submission using HL7 SPL, and M2M submission through GS1 Australia’s National Product Catalogue (NPC). swissdamed supports an online editor, XML upload, and REST API-based M2M integration.

M2M Is More Than an API Connection

It is easy to think of M2M as simply moving information from an internal system to a regulator. In practice, a production-ready solution must do considerably more.

Device data may originate in ERP, PLM, PIM, RIM, or other enterprise systems. Before submission, that data typically needs to be:

1. Mapped to the UDI regulator’s data model
2. Transformed into required formats and code values
3. Validated against regulatory business rules
4. Converted into the required message or payload
5. Securely transmitted
6. Monitored for acknowledgements, errors, and status
7. Corrected and resubmitted when necessary
8. Tracked through an appropriate audit history

The technical architecture also differs by regulator.

FDA GUDID supports HL7 SPL/XML submissions through the FDA Electronic Submissions Gateway (ESG). EUDAMED M2M uses XML through its DTX infrastructure and requires technical onboarding. AusUDID provides two M2M pathways: direct HL7 SPL/XML submissions and submissions via the National Product Catalogue (NPC). swissdamed takes another approach, using JSON messages through a REST API.

These differences become increasingly important as manufacturers expand into multiple markets.

Option 1: Build Your Own M2M Connections

Building internally gives manufacturers direct control over their regulatory integration architecture.

For organizations with mature development teams, specialized integration expertise, or heavily customized enterprise systems, that control can be attractive.

What Building Offers

• Architectural control. Internal teams determine how data is extracted, transformed, validated, transmitted, and monitored.
• Customization. Connections can be designed around highly customized ERP, PLM, RIM, PIM, or master data environments.
• Technology ownership. The manufacturer controls the codebase, infrastructure, deployment schedule, and technical roadmap.

Organizations with mature integration platforms may also be able to reuse existing infrastructure and development capabilities.

What You Are Committing to Own

The challenge is that building the connection is only the beginning.

For each regulatory destination, internal teams may need to develop and maintain:

• Data mappings and transformations
• Regulatory code lists
• Business-rule validation
• Message and payload generation
• Authentication and security
• Submission and acknowledgement processing
• Error handling and resubmission
• Monitoring and submission history
• Changes to regulatory specifications

EUDAMED illustrates how quickly the scope can expand. M2M involves more than producing an XML file. Manufacturers must address Access Point connectivity, security requirements, technical onboarding, Playground testing, credentials, and continuing compatibility with EUDAMED’s DTX specifications.

Supporting multiple regulatory databases compounds the challenge because the technical interfaces and requirements are not identical.

Option 2: Buy a Commercial UDI Platform

The alternative is to use a commercial platform designed to manage regulatory device data and connect with UDI databases worldwide.

Instead of developing each regulatory interface internally, manufacturers integrate their source systems with the platform. The platform then provides much of the regulatory transformation, validation, submission, monitoring, and connector maintenance.

What Buying Offers

• Faster implementation. Because the regulatory connectivity already exists, teams can focus more heavily on source-data readiness, mapping, integration, testing, and onboarding.
• Prebuilt regulatory logic. Specialized platforms can provide UDI database-specific data models, code lists, validation rules, message structures, and submission workflows.
• Reduced connector maintenance. When authorities update schemas, business rules, code lists, or interface specifications, the platform provider maintains the regulatory connector. Manufacturers still need to evaluate changes affecting their data and processes, but they do not have to develop every technical update themselves.
• Easier expansion. A multi-regulatory platform can also reduce the incremental effort of adding another UDI database. Common product information can be reused and then augmented, validated, and transformed for each destination.

What Buying Does Not Eliminate

A commercial platform does not remove the manufacturer’s responsibilities.

Internal teams still need to establish reliable source data, define ownership, map attributes, remediate data-quality issues, configure integrations and workflows, complete applicable regulator onboarding, validate their intended use, and train users.

There are also implementation and subscription costs, and organizations should evaluate how well the platform fits their existing architecture and operating model.

Build vs. Buy: Comparing the Options

Consideration	Build Internally	Buy a Commercial Platform
Initial development	Higher	Lower
Time to implementation	Typically longer	Typically shorter
Architecture control	Highest	Platform-dependent
Internal regulatory/technical expertise	High	Reduced
Connector maintenance	Internal	Primarily vendor
Adding regulatory markets	Additional development	Existing connectors may be available
Customization	Very high	Platform-dependent
Internal IT dependency	High	Lower
Ongoing regulatory monitoring	Primarily internal	Shared with vendor
Cost model	Development + maintenance + infrastructure	Implementation + subscription

Neither approach is automatically right.

A manufacturer with a sophisticated internal integration organization may reasonably decide to build. Another organization with a similar portfolio may place greater value on implementation speed, regulatory coverage, and reducing ongoing technical maintenance.

Don’t Compare Subscription Cost With Development Cost Alone

One of the easiest mistakes in a Build vs. Buy analysis is comparing the commercial platform’s subscription fee against the initial estimate for internal development.

That does not provide a true comparison.

An internal M2M solution can create recurring costs for:

• Regulatory monitoring
• Interface and schema updates
• Regression testing
• Infrastructure and security
• Support and incident resolution
• Validation maintenance
• Knowledge transfer and staff turnover
• New regulatory connections

A commercial solution introduces subscription costs along with implementation, integration, validation, and internal administration.

The better comparison is therefore total cost of ownership over several years.

Five Questions to Guide Your Decision

1. How many regulatory databases must you support?

Building one connection is different from maintaining connections to GUDID, EUDAMED, AusUDID, swissdamed, and future regulatory databases.

2. Do you have the necessary expertise internally?

M2M requires both enterprise integration capabilities and an understanding of regulator-specific data and technical requirements.

3. How frequently does your device data change?

A relatively static portfolio creates a different workload from one with frequent launches, packaging changes, acquisitions, and market expansion.

4. How quickly do you need to become operational?

Upcoming compliance dates and market-entry plans may make implementation speed as important as development cost.

5. Do you want regulatory connectivity to be an internal technology capability?

This may be the most important question.

Building means deliberately making regulatory integration software part of your internal technology portfolio, and accepting responsibility for maintaining it.

Buying allows internal teams to focus more heavily on device-data quality, governance, regulatory processes, and upstream integration while a specialized provider maintains the regulatory connectivity layer.

Prepare Your Data Before You Automate

Regardless of whether you build or buy, M2M cannot compensate for poor source data.

Before implementation, manufacturers should:

1. Assess source data for missing, inconsistent, or outdated device attributes.
2. Define authoritative systems for each required data element.
3. Establish ownership and governance for creating, reviewing, and approving device information.
4. Map internal attributes to each target UDI data model.
5. Define submission and exception workflows before automating them.
6. Complete required regulator testing and onboarding before production.
7. Plan for change as regulatory specifications, business rules, and code lists evolve.

Automating unreliable data simply allows unreliable data to move faster. Data readiness and governance should therefore be part of the M2M strategy from the beginning.